NRx Pharmaceuticals, Inc.
NRXP
$3.37
-$0.10-2.88%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -1,055.24% | -497.22% | 106.11% | 66.50% | -218.94% |
| Total Depreciation and Amortization | 4.85% | 65.00% | 132.56% | 4,400.00% | -200.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -100.00% |
| Total Other Non-Cash Items | 424.81% | 39.23% | -331.52% | -83.02% | 736.94% |
| Change in Net Operating Assets | -1,140.79% | -75.63% | 139.51% | 209.88% | -- |
| Cash from Operations | -106.64% | -15.67% | -28.43% | 28.23% | -15.75% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | 107.15% | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 200.00% | 50.69% | -- | -- | -- |
| Cash from Investing | -221.13% | 14.46% | 90.28% | -- | -- |
| Total Debt Issued | -- | -- | 100.00% | -104.13% | -- |
| Total Debt Repaid | -- | -- | -- | 100.00% | 76.88% |
| Issuance of Common Stock | -- | -- | -100.00% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 145.44% | -27.60% | 26.51% | 269.37% | 389.14% |
| Cash from Financing | 762.50% | -25.16% | -52.96% | 599.71% | -81.67% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,942.53% | -276.84% | -85.66% | 262.02% | -164.26% |